Is G1 Therapeutics, Inc. (GTHX) a Buy, Sell, or Hold?
G1 Therapeutics, Inc.
NASDAQ:GTHX
$7.16 USD
$0.01 (0.14%)
- Volume
- 1.1M
- Average Volume
- 2.18M
- Market Capitalization
- $377.75M
- P/E Ratio
- -7.70
- Dividend Yield
- 0.00%
- Price Target
- $4.50
- Year High
- $7.19
- Year Low
- $1.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.87
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | John E. Bailey Jr. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GTHX |
| CUSIP | 3621LQ109 |
| CIK | 0001560241 |
| Web | https://www.g1therapeutics.com |
| Phone | 919 213 9835 |
| Currency | USD |
| Employees | 100 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.62 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.87 |
| Quick Ratio | 3.45 |
| Cash Ratio | 1.09 |
Sales & Book Value
| Annual Sales | $82.51M |
| Price / Sales | 4.58 |
| Cash Flow | -0.74 |
| Price / Cash Flow | -9.85 |
| Price / Book | 10.47 |
Price Target and Rating
| Average Stock Price Forecast | $4.50 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | 59.11% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.93 |
| Trailing P/E Ratio | -7.70 |
| PEG Ratio | -0.45 |
| P/E Growth | -0.45 |
| Net Income | $-47.97M |
| Net Margin | -58.13% |
| Pretax Margin | -54.36% |
| Return on Equity | -92.13% |
| Return on Assets | -39.47% |
Financials Score
| AltmanZ Score | -8.10 |
| Piotroski Score | 2.00 |
| Working Capital | 55.42M |
| Total Assets | 98.69M |
| Ebit | -34.02M |
| Market Cap | 377.75M |
| Total Liabilities | 74.1M |
Poll Results
About G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock
G1 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on identifying, advancing, and ultimately commercializing small-molecule therapeutics to address various cancers. Their flagship commercial offering, COSELA, is designed to reduce chemotherapy-induced bone marrow suppression in adult patients with extensive-stage small cell lung cancer, administered prior to specific platinum/etoposide- or topotecan-containing regimens. The company is also actively progressing several investigational compounds. Trilaciclib, a CDK4/6 inhibitor, is currently undergoing extensive clinical evaluation, including Phase III studies for first-line colorectal cancer and first-line triple-negative breast cancer. Additionally, it is in Phase II trials for initial bladder cancer tr ... eatment, in combination with an antibody-drug conjugate, and as a neoadjuvant therapy for breast cancer. Their development pipeline further includes lerociclib, an oral CDK4/6 inhibitor intended for multiple oncological applications, and rintodestrant, an orally administered selective estrogen receptor degrader, which is in Phase IIa clinical trials for estrogen receptor-positive, HER2-negative breast cancer. G1 Therapeutics has forged several strategic licensing agreements. They have partnered with EQRx, Inc. and Genor Biopharma Co. Inc. for the oral formulation of lerociclib, encompassing all human indications. A separate collaboration with Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. covers the parenteral development and market introduction of trilaciclib for any human indication. Furthermore, the company works with ARC Therapeutics on a CDK2 inhibitor, designated for both human and veterinary uses. Established in 2008, G1 Therapeutics, Inc. is headquartered in Research Triangle Park, North Carolina.
Frequently Asked Questions
-
What is the current G1 Therapeutics, Inc. (GTHX) stock price?
-
G1 Therapeutics, Inc.(NASDAQ:GTHX) stock price is $7.16 in the last trading session. During the trading session, GTHX stock reached the peak price of $7.19 while $1.08 was the lowest point it dropped to. The percentage change in GTHX stock occurred in the recent session was 0.14% while the dollar amount for the price change in GTHX stock was $0.01.
-
GTHX's industry and sector of operation?
-
The NASDAQ listed GTHX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GTHX?
-
Andrew Perry | Chief Commercial Officer
Monica Thomas | Chief Legal & People Officer
William C. Roberts | Vice President of Investor Relations & Corporation Communications
Jeff Macdonald | Senior Director of Investor Relations & Corporate Communications
Terry L. Murdock | Chief Operating Officer -
How many employees does GTHX have?
-
Number of GTHX employees currently stands at 100. GTHX operates from 700 Park Offices Drive, Research Triangle Park, NC 27709, US.
-
Link for GTHX official website?
-
Official Website of GTHX is: https://www.g1therapeutics.com
-
How do I contact GTHX?
-
GTHX could be contacted at phone #919 213 9835 and can also be accessed through its website. GTHX operates from 700 Park Offices Drive, Research Triangle Park, NC 27709, US.
-
How many shares of GTHX are traded daily?
-
The average number of GTHX shares traded daily for last 3 months was 2.18M.
-
What is the market cap of GTHX currently?
-
The market value of GTHX currently stands at $377.75M with its latest stock price at $7.16